Novavax Initiates Coverage with Buy Rating and $10 Price Target

H.C. Wainwright initiated coverage of Novavax (NVAX) with a Buy rating and a $10 price target. The biotechnology company's platform generates strong immune responses, and its vaccines are safe, well-tolerated, and adaptable for a broad range of antigens. Novavax has a strong financial health profile, with a 9.6% one-year revenue growth rate and a gross margin of 87.8%. However, the company has a high debt-to-equity ratio and warning signs of potential financial manipulation.

In a recent update, HC Wainwright & Co. has upgraded its rating for Novavax (NVAX) to a "Buy" with a new price target set at $10.00 USD. This new rating was announced by analyst Sean Lee on August 28, 2025. This marks a significant change, bringing a fresh perspective to the shares of Novavax as the company receives optimistic outlooks amidst its recent market activities [1].

Looking back at the recent history of analyst ratings for Novavax (NVAX):
- On August 20, 2025, B of A Securities downgraded NVAX, lowering the price target from $9.00 to $7.00, with the rating changed to "Underperform" from "Neutral".
- On July 22, 2025, B of A Securities maintained a "Neutral" rating but lowered the price target from $10.00 to $9.00.
- On June 17, 2025, Citigroup initiated coverage on NVAX with a "Sell" rating and set a price target of $6.00.
- On May 9, 2025, JP Morgan maintained its "Underweight" rating while lowering the price target from $9.00 to $7.00.

Investors and market watchers are keenly observing how Novavax (NVAX) will perform following the positive sentiment from HC Wainwright & Co. The upgraded rating could signal renewed interest and potential for growth in the future.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Novavax Inc (NVAX) is $14.57 with a high estimate of $25.00 and a low estimate of $6.00. The average target implies an upside of 92.24% from the current price of $7.58. More detailed estimate data can be found on the Novavax Inc (NVAX) Forecast page [2].

Based on the consensus recommendation from 8 brokerage firms, Novavax Inc's (NVAX) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Novavax Inc (NVAX) in one year is $8.68, suggesting an upside of 14.51% from the current price of $7.58. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Novavax Inc (NVAX) Summary page [3].

References:
[1] https://www.gurufocus.com/news/3084185/hc-wainwright-co-upgrades-novavax-nvax-to-buy-with-10-target-nvax-stock-news
[2] https://finance.yahoo.com/news/novavax-inc-nvax-launches-protein-090552441.html
[3] https://www.biospace.com/press-releases/novavaxs-nuvaxovid-2025-2026-formula-covid-19-vaccine-approved-in-the-u-s